REG - Biofrontera AG - Notice of Q3 Results <Origin Href="QuoteRef">B8FGn.DE</Origin>

Biofrontera AGAnnouncement

29/10/2014 14:59

RNS Number : 3380V
Biofrontera AG
27 October 2014
27 October 2014
Biofrontera AG
("Biofrontera" or the "Company")
Notice of Q3 Results
Biofrontera AG (AIM:B8F), the European biopharmaceutical company, will be announcing its Q3 results for the nine month period ending 30 September 2014 on 13 November 2014.
ends.
For enquiries, please contact: 
Biofrontera AG

Prof. Hermann Lbbert, Chief Executive Officer
Thomas Schaffer , Chief Financial Officer
Tel:+ 49 (0) 214 87632 22 


Nomad and Broker: Shore Capital
Tel: +44(0) 20 7408 4090
Bidhi Bhoma / Toby Gibbs



Investor Relations: Seton Services
Tel: +44(0) 20 7603 6797
Toni Vallen



Financial PR: Gable Communications
John Bick
Tel: +44(0) 20 7193 7463
Tel: +44 (0)7872 061007
Notes to Editors:
Biofrontera AG (AIM/FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development and distribution of dermatological drugs and medical cosmetics for the treatment and care of skin diseases. Biofrontera's main product is Ameluz, a prescription drug approved for use in Europe for the treatment of mild to moderate Actinic Keratosis (superficial skin cancer) by photodynamic therapy (light therapy). Biofrontera is the first small German pharmaceutical company to receive a centralized approval for a drug developed in-house. The Company is looking to further develop Ameluz for use in Basal Cell Carcinoma and is currently progressing through regulatory approvals to sell the product in other territories, in particular the largest pharmaceutical market, the USA.
In addition, the Company markets the Belixos cosmetic series with plant extracts, currently available in cream and liquid formulations which offer nurturing and regenerating effects for people suffering from pruritus, dry skin or chronic ailments such as eczema or psoriasis.
Biofrontera group was founded in 1997 by Prof. Dr. Hermann Lbbert, the CEO, and is headquartered in Leverkusen, Germany.
www.biofrontera.com

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NORLIFITISLDFIS